APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/083,529	02/27/2002	Undurti Narasimha Das	UND 99.02 D 1	8507
Rama B. Nath	7590 06/14/2007		EXAM	INER
2530 Quail Run Lansdale, PA 19446		PRYOR, ALTON NATHANIEL		
			ART UNIT	PAPER NUMBER
			1616	
			MAIL DATE	DELIVERY MODE
			06/14/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary		Application No.	Applicant(s)			
		10/083,529	DAS, UNDURTI NARASIMHA			
		Examiner	Art Unit			
		Alton N. Pryor	1616			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
A SH WHIC - Exte after - If NC - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. O period for reply is specified above, the maximum statutory period we are to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin will apply and will expire SIX (6) MONTHS from cause the application to become ARANDONE	N. nely filed the mailing date of this communication. D. (35 U.S.C. 6.133)			
Status						
1)⊠	Responsive to communication(s) filed on 26 M	arch 2007.				
2a)⊠	This action is FINAL . 2b) This	action is non-final.				
3)[Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 45	53 O.G. 213.			
Disposit	ion of Claims					
4)⊠	Claim(s) <u>1-17</u> is/are pending in the application.					
	4a) Of the above claim(s) <u>8-17</u> is/are withdrawn from consideration.					
5)	5) Claim(s) is/are allowed.					
6)⊠	Claim(s) <u>1-7</u> is/are rejected.					
7)	Claim(s) is/are objected to.					
8)□	Claim(s) are subject to restriction and/or	election requirement.				
Applicati	ion Papers					
9)	The specification is objected to by the Examiner	r.				
	10) ☐ The drawing(s) filed on iṣ/are: a) ☐ accepted or b) ☐ objected to by the Examiner.					
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
	Replacement drawing sheet(s) including the correcti					
11)	The oath or declaration is objected to by the Exa					
Priority u	ınder 35 U.S.C. § 119	•				
12)	Acknowledgment is made of a claim for foreign ☐ All b) ☐ Some * c) ☐ None of:	priority under 35 U.S.C. § 119(a)	-(d) or (f).			
	1. Certified copies of the priority documents	have been received.				
	2. Certified copies of the priority documents	• •				
٠	3. Copies of the certified copies of the priori		d in this National Stage			
	application from the International Bureau	* **				
* 8	See the attached detailed Office action for a list of	of the certified copies not receive	d.			
Attachmen						
	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary (Paper No(s)/Mail Da				
3) 🔲 Inform	nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal Pa				

Art Unit: 1616

Detailed Action

Applicant's arguments filed 3/26/07 have been fully considered but they are not persuasive. See argument below.

Elected by Original Presentation

Newly submitted claims 8-17 are directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: Newly submitted claims are to methods of a) potentiating anti-angiogenic substances by use of Poly Unsaturated Fatty Acids for treating hepatocellular carcinoma, b) inhibiting endothelial cell proliferation or c) treating Hodgkin's disease whereas original claims are to a methods of d) inhibiting blood supply to a tumor and e) treating a tumor.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claims 8-17 are withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

Pending Rejection

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir.

Application/Control Number: 10/083,529

Art Unit: 1616

1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 1-7 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1,2 of U.S. Patent No. 6380253. Although the conflicting claims are not identical, they are not patentably distinct from each other because both USPN '253 discloses the species glioma whereas USAN '529 makes claims the genus, tumor. Therefore USPN '253 makes the USAN '529 obvious since USPN '253 and USAN '529 differ in scope, i.e. USPN makes claim a species in the tumor genus.

Response to Applicant's Argument

Applicant has submitted new claims which are distinct from the original claims filed. For this reason, the Examiner maintains the double patenting rejection over the original claims and restricts the invention to the originally filed claims.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within

TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Telephonic Inquiry

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Alton N. Pryor whose telephone number is 571-272-0621. The examiner can normally be reached on 8:00 a.m. - 4:30 p.m..

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on 571-272-0646. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Page 5

Alton Pryor Primary Examiner AU 1616